 Under the development code ZX008, the pharmaceutical company Zogenix is studying fenfluramine's potential to treat seizures.Clinical trials have studied the use of fenfluramine in patients with Dravet syndrome.Results of a Phase III clinical trial showed a 64% reduction in seizures.